A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation.

Autor: Imataki O; Division of Hematology, Faculty of Medicine, Kagawa University, Kagawa, Japan., Ishida T; Division of Hematology, Faculty of Medicine, Kagawa University, Kagawa, Japan.; Kagawa University Hospital Post Graduate Clinical Education Center, Kagawa, Japan., Kubo H; Division of Hematology, Faculty of Medicine, Kagawa University, Kagawa, Japan., Uemura M; Division of Hematology, Faculty of Medicine, Kagawa University, Kagawa, Japan., Nanya Y; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan., Kawakami K; Department of Hematology, Kagawa Prefectural Central Hospital, Kagawa, Japan., Ogawa S; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan., Kadowaki N; Division of Hematology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Jazyk: angličtina
Zdroj: Case reports in oncology [Case Rep Oncol] 2020 Apr 22; Vol. 13 (1), pp. 449-455. Date of Electronic Publication: 2020 Apr 22 (Print Publication: 2020).
DOI: 10.1159/000506452
Abstrakt: Hematological malignancies, including chronic myeloid leukemia (CML), exhibit ASXL1 mutations; however, the function and molecular mechanism of these mutations remain unclear. ASXL1 was originally identified as tumor suppressor gene, in which loss of function causes myelodysplastic syndrome (MDS). ASXL1 mutations are common and associated with disease progression in myeloid malignancies including MDS, acute myeloid leukemia, and similarly in CML. In MDS, ASXL1 mutations have been associated with poor prognosis; however, the impact of ASXL1 mutations in CML has not been well described. A 31-year-old male was diagnosed as CML-chronic phase (CP). Laboratory findings showed a white blood cell count of 187,200/µL, with asymptomatic splenomegaly. Blast count was 5.0% in peripheral blood and 7.3% in bone marrow. There was no additional chromosomal abnormality except for t(9;22)(q34;q11.2) by chromosomal analysis. At onset, the Sokal score was 1.4, indicating high risk. The patient received tyrosine kinase inhibitor (TKI) therapy, comprising nilotinib ∼600 mg/day, bosutinib ∼600 mg/day, ponatinib ∼45 mg/day, and dasatinib ∼100 mg/day. Nevertheless, after 1.5 years of continuous TKI therapy, the best outcome was a hematological response. Although additional chromosomal aberrations and ABL1 kinase mutations were analyzed repeatedly before and during TKI therapy, known genetic abnormalities were not detected. Thereafter, the patient underwent bone marrow transplantation from an HLA 7/8 matched unrelated donor (HLA-Cw 1 locus mismatch, graft-versus-host direction). The patient achieved neutrophil engraftment, 18 days after transplantation, leading to complete remission with an undetectable level of BCR-ABL1 mRNA. The patient, however, died from graft-versus-host disease and thrombotic microangiopathy after 121 days. Gene sequence analysis of his CML cell before stem cell transplantation revealed ASXL1 mutations. Physiologically, ASXL1 contributes to epigenetic regulation. In the CML-CP patient in this case report, ASXL1 mutation conferred resistance to TKI through obscure resistance mechanisms. Even though a molecular mechanism for TKI resistance in ASXL1 mutation in CML has remained obscure, epigenetic modulation is a plausible mode of CML disease progression. The clinical impact including prognosis of ASXL1 for CML is underscored. And the treatment strategy of CML with ASXL1 mutation has not been established. A discussion of this case was expected to facilitate treatment options.
Competing Interests: The authors declare no competing interests. The authors declare no potential conflicts of interest.
(Copyright © 2020 by S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje